Beam Therapeutics Inc BEAM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BEAM is a good fit for your portfolio.
News
-
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
-
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Thinking about trading options or stock in Pfizer, Palo Alto Networks, Block, McGrath RentCorp, or Beam Therapeutics?
-
Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million Upfront
-
Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026
Trading Information
- Previous Close Price
- $23.47
- Day Range
- $22.63–23.85
- 52-Week Range
- $16.95–49.50
- Bid/Ask
- $22.35 / $22.78
- Market Cap
- $1.87 Bil
- Volume/Avg
- 1.1 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 436
- Website
- https://www.beamtx.com
Comparables
Valuation
|
Metric
|
BEAM
|
VERV
|
SANA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.00 | 0.94 | 5.46 |
Price/Sales | 4.92 | 37.55 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BEAM
|
VERV
|
SANA
|
|---|---|---|---|
Quick Ratio | 5.79 | 17.02 | 3.18 |
Current Ratio | 5.89 | 17.24 | 3.31 |
Interest Coverage | — | — | — |
Quick Ratio
BEAM
VERV
SANA
Profitability
|
Metric
|
BEAM
|
VERV
|
SANA
|
|---|---|---|---|
Return on Assets (Normalized) | −3.95% | −26.37% | −45.68% |
Return on Equity (Normalized) | −6.58% | −33.33% | −81.96% |
Return on Invested Capital (Normalized) | −9.14% | −32.02% | −66.18% |
Return on Assets
BEAM
VERV
SANA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pcpbhmpdzl | Krwk | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qzjrzykv | Tzvlgcq | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fpmfxcvf | Myhlsr | $99.6 Bil | |
MRNA
| Moderna Inc | Fvbhkwb | Jzyk | $38.8 Bil | |
ARGX
| argenx SE ADR | Fjpqwygrl | Vpf | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Wjlrydq | Thrpr | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fmyndnwc | Hgtnjgc | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jclrjlyy | Xrpvgh | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvgyzqrfcj | Zxxqqf | $12.4 Bil | |
INCY
| Incyte Corp | Gbftzjl | Zkxzszg | $11.9 Bil |